Kincell Bio Expands Research Triangle Park, North Carolina Facility

Kincell Bio, a contract development and manufacturing organization (CDMO) supporting autologous and allogeneic cell therapy programs, is expanding its Research Triangle Park (RTP), North Carolina facility to support clients as they advance from late-stage clinical CMC development through commercialization and post-approval life cycle management.

The RTP facility serves as Kincell Bio’s center of excellence for pivotal supply, commercialization, and commercial manufacturing, complementing its early-phase focused facility in Gainesville, Florida. While it currently houses four ISO 7 cleanroom suites, the expansion will enable the addition of two more suites, meaningfully increasing the facility’s capacity to support both autologous and allogeneic cell therapy programs at commercial scale.

“This expansion reflects our commitment to supporting our clients’ commercial success and our confidence in the trajectory of the overall cell therapy industry,” commented Larry Pitcher, CEO of Kincell Bio. “A number of our clients are preparing for commercialization, and these investments will ensure that our infrastructure is ready to support them at every stage of that journey.”

The build-out includes a comprehensive suite of supporting infrastructure designed to meet the rigorous demands of late-stage and commercial programs:

• Additional QC Laboratory to support expanded quality control testing across a growing client portfolio
• MSAT/ASAT Laboratory purpose-built to support later-stage process characterization, process validation, method validation, and technology transfer activities
• Microbiology Laboratory equipped for rapid sterility testing, accelerating critical release timelines for autologous therapies, while also supporting allogeneic products
• Expanded GMP Warehouse providing significantly increased storage capacity to support growing late-phase clinical development and commercial supply needs
• Administrative Expansion workspaces for over 100 team members

Kincell Bio is also making complementary investments in the digital infrastructure required to support commercial-stage operations. Further investment in the organization’s Veeva quality management system will streamline quality operations, enhance end-to-end visibility and control, and provide the scalability necessary as an increasing number of cell therapy products advance toward and enter the commercial market. Additionally, investment in the company’s enterprise resource planning (ERP) system will support end-to-end program and product management, ensuring operational efficiency keeps pace with growing client demand.

The expanded facility is projected to be fully operational by the end of the third quarter of 2026.